KisspeptinSexual Health

Overview

Kisspeptin is a neuropeptide encoded by the KISS1 gene; its clinically studied forms are the 54-amino-acid kisspeptin-54 and the shorter active fragment kisspeptin-10. It sits near the top of the reproductive-hormone cascade, acting on the hypothalamus to drive release of gonadotropin-releasing hormone (GnRH). It has an unusually large human research base — much of it from Imperial College London — spanning reproductive endocrinology and, more recently, sexual and emotional brain processing. Despite this, kisspeptin has no approved drug indication; it is investigational and sold here as research-use-only.

Mechanism

Kisspeptin is an agonist at the receptor KISS1R (formerly GPR54), expressed on hypothalamic GnRH neurons. Binding stimulates GnRH release, which triggers pituitary secretion of LH and FSH and downstream gonadal sex-steroid production — making the kisspeptin/KISS1R system a master regulator of puberty and reproduction. The pathway's importance in humans is underscored by genetics: loss-of-function mutations in the receptor cause hypogonadotropic hypogonadism (failure to enter puberty). Kisspeptin-10 and kisspeptin-54 are cleared rapidly, within minutes to tens of minutes.

Clinical evidence

In human studies (not approved treatments), intravenous or subcutaneous kisspeptin raises LH, FSH and testosterone in healthy men, with kisspeptin-10 and kisspeptin-54 producing broadly similar gonadotrophin responses — though weaker than direct GnRH stimulation. Beyond reproduction, a randomized, placebo-controlled study reported that kisspeptin enhanced limbic brain responses to sexual and bonding cues and attenuated negative mood in men, and a randomized crossover trial in premenopausal women with hypoactive sexual desire disorder found it modulated sexual- and attraction-related brain processing. These are mechanistic and proof-of-concept findings; there are no large efficacy or long-term outcome trials.

Safety profile

Across the controlled human studies to date, short-term kisspeptin administration has generally been well tolerated, with the hypoactive-sexual-desire-disorder trial reporting no adverse effects. However, those studies used acute or short infusions in supervised research settings; the safety of repeated or chronic self-administration in healthy individuals has not been established. Kisspeptin is not an FDA-approved therapeutic and carries no approved dosing for any condition. Research use only — it is not a treatment for fertility, libido or hormonal conditions, and nothing here is medical advice.

Compare

• vs HCG

  Also acts on the reproductive axis but downstream — an LH/CG-receptor agonist that directly stimulates the gonads, and is FDA-approved for specific uses

• vs PT-141

  Another peptide studied for sexual desire/arousal, but it works through the melanocortin (MC4R) pathway and is FDA-approved as Vyleesi